Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Gastroenterology. 2019 Nov 9;158(3):679–692.e1. doi: 10.1053/j.gastro.2019.10.038

Figure 1. ZIP4 predicts survival and promotes pancreatic cancer cell growth and chemoresistance to gemcitabine.

Figure 1.

(A). Overall survival. All 93 patients were categorized into two groups based on ZIP4 level: negative/low and strong ZIP4 staining. The low ZIP4 group has significantly greater survival than the high ZIP4 group (P= .04). (B). Cell viability of MIA-V and MIA-ZIP4 cells, and (C). AsPC-shV and AsPC-shZIP4 cells following gemcitabine treatment. Data were collected on day 2. Cell viability under chemotherapeutic treatment normalized to regular media was calculated. (D). Spheroid growth assay. Spheroid growth was assessed at 48 h post gemcitabine treatment. The scale bar is 200 μm. (E). LC-MS/MS. The gemcitabine level in MIA-V and MIA-ZIP4 cells treated with 200 μM gemcitabine for 18 h was detected using LC-MS/MS. (F). LC-MS/MS. Gemcitabine level in AsPC-shV and AsPC-shZIP4 cells treated with 400 μM gemcitabine for 18 h was detected using LC-MS/MS. (G). Single cell MS. Gemcitabine level in MIA-V and MIA-ZIP4 cells treated with 400 μM gemcitabine for 24 h was detected using single cell MS.